SMT 14224: type II diabetes
Diabetes is a disease whereby patients can no longer effectively control the usage of basic carbohydrates in the body. There are two main types of diabetes, type I where patients require insulin for therapy and type II where patients are currently treated with a range of drugs to augment their own natural control mechanisms in an attempt to avoid insulin therapy. Approximately 90% of diabetic patients are type II, which is a form of the disease where there is a rapidly growing number of diagnosed cases.
There are currently approximately 250 million people world wide that suffer from diabetes which is estimated to grow to 380 million by 2026. No available therapy for either type I or type II diabetes completely restores normal function, so even in the best responding patients there is still a risk of many complications including hypertension, retinal damage, renal failure and cardiovascular disease.
Summit’s Diabetes Programme
Summit have a diabetes programme focused on identifying novel compounds for use as drugs in both type I and type II diabetes treatment and more importantly, compounds which can reverse the underlying cause of the disease, restoring normal function and thus fulfilling a large unmet medical need.
The lead compound SMT 14224 shows excellent efficacy results in well validated acute and chronic in vivo models. The positive results from this Seglin indicate that it may operate via a new mechanism of action. Additional studies are on-going to reinforce data already generated to confirm the potential unique clinical position of SMT 14224 and also provide further insight into the compounds mechanism of action.
